We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

30 hedge funds and large institutions have $12.2M invested in Cymabay Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

3% more funds holding

Funds holding: 29 → 30 (+1)

33% less capital invested

Capital invested by funds: $18.1M → $12.2M (-$5.91M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

70% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 10

Holders
30
Holders Change
+1
Holders Change %
+3.45%
% of All Funds
0.8%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
4
Increased
3
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$62.7K
2
Renaissance Technologies
Renaissance Technologies
New York
+$62.1K
3
Citadel Advisors
Citadel Advisors
Florida
+$13.6K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.09K
5
Barclays
Barclays
United Kingdom
+$1.61K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$652K
2
VAM
Visium Asset Management
New York
-$543K
3
LOAMU
Lombard Odier Asset Management (USA)
New York
-$466K
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$237K
5
PVI
Pura Vida Investments
New York
-$178K

CBAY Hedge Fund Activity: Q1 2016 in Review

30 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2016, worth a combined $12.2M — down 33% from $18.1M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CBAY positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $62.7K. The largest seller was Sabby Management, cutting an estimated $652K.

  • 30 institutional investors held Cymabay Therapeutics (CBAY) as of Q1 2016, up from 29 in Q4 2015.
  • Funds reported $12.2M of Cymabay Therapeutics stock for Q1 2016, down 33% quarter-over-quarter.
  • 4 funds opened new Cymabay Therapeutics positions in Q1 2016 and 3 closed out, a net change of +1 holder.
  • The largest Cymabay Therapeutics buyer in Q1 2016 was Vanguard Group, an estimated $62.7K added.
  • The largest Cymabay Therapeutics seller in Q1 2016 was Sabby Management, an estimated $652K sold.

Based on aggregated 13F filings for Q1 2016.